Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making

Editorial

Joseph A Sparano et al. J Clin Oncol. 2010.

. 2010 Apr 1;28(10):1625-7.

doi: 10.1200/JCO.2009.25.2882. Epub 2010 Jan 11.

No abstract available

Comment on

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N. Mamounas EP, et al. J Clin Oncol. 2010 Apr 1;28(10):1677-83. doi: 10.1200/JCO.2009.23.7610. Epub 2010 Jan 11. J Clin Oncol. 2010. PMID: 20065188 Free PMC article.
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS. Lo SS, et al. J Clin Oncol. 2010 Apr 1;28(10):1671-6. doi: 10.1200/JCO.2008.20.2119. Epub 2010 Jan 11. J Clin Oncol. 2010. PMID: 20065191
Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Voduc KD, et al. J Clin Oncol. 2010 Apr 1;28(10):1684-91. doi: 10.1200/JCO.2009.24.9284. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194857